EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel protein biomarkers for risk stratification and personalized medicine

Erik Moedt iD, Wenjun Ju, Viji Nair, Petter Bjornstad, Matthias Kretzler, Hiddo J L Heerspink iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfag068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Erik Moedt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Biomarkers, Clusterin, Epidermal Growth Factor, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: STADAPHARM GmbH, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Albuminuria is widely used to monitor chronic kidney disease (CKD) and treatment response but is subject to variability and primarily reflects glomerular injury. Urinary clusterin and epidermal growth factor (uEGF) are associated with tubular injury and repair, respectively, and may serve as mechanism-informed pharmacodynamic biomarkers. We investigated responses of urinary clusterin and uEGF to endothelin receptor antagonists (ERAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2i), respectively, in CKD.

Methods

We evaluated changes in urinary clusterin-to-creatinine ratio (uCLU/Cr) and uEGF-to-creatinine ratio (uEGF/Cr) in two randomized CKD trial populations. Effects of ERA on uCLU/Cr and endothelin-1 (ET-1) were assessed during the atrasentan enrichment phase of SONAR (Study of Diabetic Nephropathy with Atrasentan), and effects of SGLT2i on uEGF/Cr were examined in DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) across different CKD etiologies, diabetes status, and glycemic control. Associations between uEGF/Cr and intrarenal EGF messenger RNA (mRNA) expression were examined using kidney biopsy single-cell RNA sequencing data.

Results

After 6 weeks of treatment with atrasentan, uCLU/Cr decreased by 46.3% (95% confidence interval [CI]: −57.8 to −37.1), while serum ET-1 increased by 23.4% (95% CI 19.2–27.4). There were no effects on serum clusterin and only a numerical decrease in urinary ET-1. Baseline uCLU/Cr correlated significantly with urinary ET-1 (Pearson r = 0.65, P < .0001). In DAPA-CKD, dapagliflozin attenuated the decline in uEGF/Cr over 1 year, with heterogeneity across CKD etiologies. Relative increases were greatest in diabetic kidney disease and absent in glomerulonephritis and hypertensive nephropathy. Similarly, effects were larger in those with type 2 diabetes and higher baseline HbA1c. Tubular EGF mRNA expression correlated positively with uEGF/Cr.

Conclusions

Urinary clusterin and uEGF are mechanism-informed pharmacodynamic biomarkers reflecting distinct intrarenal pathways engaged by ERA and SGLT2i therapy, respectively. These biomarkers complement albuminuria by capturing tubular injury and repair, providing a more comprehensive biological assessment of treatment effects and heterogeneity in CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersClusterinEpidermal Growth FactorPrecision MedicineRenal Insufficiency, ChronicFemaleHumansMaleAtrasentanCreatinineFollow-Up StudiesGlomerular Filtration RatePrognosisRisk AssessmentRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

albuminuriachronic kidney diseaseclusterinendothelinepidermal growth factor

Substanzen

AtrasentanBiomarkersClusterinCreatinineEpidermal Growth Factor

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.

ORCID-Profile: Erik Moedt, Hiddo J L Heerspink

Förderung

  • STADAPHARM GmbH
  • European Union

Zitieren

APA

Moedt, E., Ju, W., Nair, V., Bjornstad, P., Kretzler, M., & Heerspink, H. J. L. (2026). Novel protein biomarkers for risk stratification and personalized medicine. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag068

Vancouver

Moedt E, Ju W, Nair V, Bjornstad P, Kretzler M, Heerspink HJL. Novel protein biomarkers for risk stratification and personalized medicine. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag068

BibTeX
@article{Moedt2026,
  author = {Moedt, Erik and Ju, Wenjun and Nair, Viji and Bjornstad, Petter and Kretzler, Matthias and Heerspink, Hiddo J L},
  title = {Novel protein biomarkers for risk stratification and personalized medicine},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag068}
}
Kostenlos starten →